Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of PMZ-2010 (Centhaquine) a Resuscitative Agent for Hypovolemic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with hypovolemic shock admitted to the emergency room or ICU with systolic blood pressure ≤ 90 mmHg at presentation and continue to receive standard shock treatment. Blood Lactate level indicative of hypovolemic shock (\>2.0 mmol/L).~Exclusion Criteria:~1. Development of any other terminal illness not associated with Hypovolemic shock during the 28-day observation period.~2. Patient with altered consciousness not due to Hypovolemic shock.~3. Known pregnancy.~4. Cardiopulmonary resuscitation (CPR) before randomization.~5. Presence of a do not resuscitate order.~6. Patient is participating in another interventional study.~7. Patients with systemic diseases which were already present before having trauma, such as: cancer, chronic renal failure, liver failure, decompensated heart failure or AIDS.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Normal Saline (Type: ACTIVE_COMPARATOR): Hypovolemic shock patients will be provided the standard of care. Following randomization 100 ml (equal volume to experimental arm) of normal saline will be administered intravenously over 1 hour.
- PMZ-2010 (centhaquine) (Type: EXPERIMENTAL): Hypovolemic shock patients will be provided the standard of care. Following randomization PMZ-2010 (0.01 mg/kg) will be administered intravenously over 1 hour in 100 mL of normal saline.

Based on this trial design, predict the completion outcome and termination type (if applicable).